| The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. | |
| | |
MedLine Citation:
|
PMID: 18715660 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cardiometabolic risk factors affect more than 47 million adults in the United States today. Although certain risk factors (e.g., obesity, dyslipidemia, hypertension, and hyperglycemia) contribute independently to the global risk, dyslipidemia is one of the most important risk factors for cardiovascular disease. Successful treatment requires a well-coordinated multifaceted approach, with commitment to a long-term program for disease management. Although initial attempts should focus on dietary changes and increased physical activity, most patients also need effective, safe, and well-monitored pharmacotherapy. Experimental studies have shown that overactivation of the endocannabinoid system-a physiologic signaling system involved in regulating energy intake, fatty acid synthesis and storage, and glucose and lipid metabolism-is associated with obesity, dyslipidemia, and insulin resistance. In clinical trials, selective blockade of CB1 receptors has resulted in substantial weight loss and significant improvement in lipid profiles. The effects of rimonabant, the first selective CB1 receptor blocker, were evaluated in 6600 obese or overweight adults who participated in one of 4 multicenter, placebo-controlled, randomized clinical trials for at least 1 year. Significant improvement in lipid profiles (specifically HDL and triglyceride levels and ratio of total cholesterol to HDL cholesterol) was seen in the 2503 patients taking rimonabant 20 mg/day, independent of its substantial effects on weight loss. No significant changes in LDL or total cholesterol were observed. Results of clinical trials with rimonabant are promising. Additional long-term controlled studies with appropriate follow-up are warranted to confirm the clinical potential of this drug, particularly its effects on dyslipidemia and other cardiovascular endpoints. |
| | |
Authors:
|
Prakash Deedwania |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2008-08-19 |
Journal Detail:
|
Title: International journal of cardiology Volume: 131 ISSN: 1874-1754 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-12 Completed Date: 2009-05-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 305-12 Citation Subset: IM |
Affiliation:
|
Cardiology Division, VACCHCS/UCSF School of Medicine, Fresno, San Francisco, California 93703, United States. deed@fresno.ucsf.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiovascular Diseases
/
etiology* Dyslipidemias / complications, drug therapy, etiology Endocannabinoids / metabolism* Humans Insulin Resistance Lipid Metabolism* / drug effects Obesity / complications, drug therapy, etiology Piperidines / therapeutic use Pyrazoles / therapeutic use Receptor, Cannabinoid, CB1 / antagonists & inhibitors* Risk Factors Signal Transduction |
| Chemical | |
Reg. No./Substance:
|
0/Endocannabinoids; 0/Piperidines; 0/Pyrazoles; 0/Receptor, Cannabinoid, CB1; 158681-13-1/rimonabant |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Dif...
Next Document: Acute myocardial infarction and transient ischemic attack in a patient with lone atrial fibrillation...